会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Antimicrobial compounds
    • 抗菌化合物
    • US07385086B2
    • 2008-06-10
    • US10764451
    • 2004-01-27
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • C07C317/00C07C317/02C07C317/04C07C317/06C07C317/08
    • C40B40/04C07C311/06C07C317/44
    • This invention provides compounds and methods for treating, with said compound, a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn-Z-CO—Y, where R is an alkyl groups having 6-20 carbon atoms, unsaturated hydrocarbon groups having 6-20 carbon atoms, or alkyl groups having 6-20 carbon atoms interrupted by at least one aromatic ring; Z is —CH2—, —CH2CH2—, —NH—NH—, —O—, ——NH—, —O—NH—, —CH2—NH—, —CH2—O—, —NH—O—, —NH—CH2—, —O—CH2—, and —CH═CH—; Y is —NH2, —O—CH2—C6H5, —CO—CO—O—CH3, and —O—CH3; and n is 1 or 2. It has been discovered that these compounds treat microbially-based infections caused by corynebacteria, nocardiae, rhodococcus, and mycobacteria. These compounds may be used to treat mycobacterial cells, such as Mycobacteria tuberculosis, drug resistant M. tuberculosis, M. avium intracellulare, M. leprae, M. paratuberculosis, and pathogenic Mycobacteria sp.
    • 本发明提供了通过向动物施用含有具有式R-SO n -Z-CO-Y的化合物的药物组合物,通过向所述化合物处理分枝杆菌感染的化合物和方法,其中R 是具有6-20个碳原子的烷基,具有6-20个碳原子的不饱和烃基或具有6-20个碳原子的烷基被至少一个芳环中断; Z是-CH 2 - , - CH 2 CH 2 - , - NH-NH-, - O - , - NH-, -O-NH-,-CH 2 -NH-,-CH 2 -O-,-NH-O-,-NH-CH 2, -O - CH 2 - 和-CH-CH-; Y是-NH 2,-O-CH 2 -C 6 H 5,-CO-CO- O-CH 3,和-O-CH 3; 已发现这些化合物治疗由棒状杆菌,诺卡氏菌,罗红球菌和分枝杆菌引起的基于微生物的感染。 这些化合物可用于治疗分枝杆菌细胞,例如结核分枝杆菌,耐药性结核分枝杆菌,胞内分枝杆菌,麻疯病,副结核分枝杆菌和致病性分枝杆菌属。
    • 2. 发明授权
    • Antimicrobial compounds
    • 抗菌化合物
    • US06713654B1
    • 2004-03-30
    • US09486550
    • 2000-08-28
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • C07C31500
    • C40B40/04C07C311/06C07C317/44
    • This invention provides methods for treating a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn—Z—CO—Y, where R is an alkyl group having 6-20 carbons; Z is a radical selected from —CH2—, —O—, and —NH—, two of these radicals coupled together, or —CH2═CH2—; Y is —NH2, O—CH2—C6H5, —CO—CO—O—CH3, or O—CH3; and n is 1 or 2. It has been discovered that these compounds inhibit growth of microbial cells which synthesize &agr;-substitued, &bgr;-hydroxy fatty acids, particularly corynemycolic acid, nocardic acid, and mycolic acid. These compounds may be used to inhibit growth of mycobacterial cells, such as Mycobacterium tuberculosis, drug-resistant M. tuberculosis, M. avium intracellulare, and M. leprae.
    • 本发明提供了通过向动物施用含有具有式R-SOn-Z-CO-Y的化合物的药物组合物来治疗分枝杆菌感染的方法,其中R是具有6-20个碳原子的烷基; Z是选自-CH 2 - , - O-和-NH-的基团,这些基团中的两个连接在一起,或-CH 2 = CH 2 - ; Y是-NH 2,O-CH 2 -C 6 H 5,-CO-CO-O-CH 3或O-CH 3; 已经发现,这些化合物抑制合成α-取代的β-羟基脂肪酸,特别是氯霉素酸,诺卡酸和霉菌酸的微生物细胞的生长。 这些化合物可用于抑制分枝杆菌细胞的生长,例如结核分枝杆菌,耐药性结核分枝杆菌,胞内分枝杆菌和麻疯病。
    • 4. 发明申请
    • Methods of Inducing Weight Loss
    • 诱导减肥的方法
    • US20100022639A1
    • 2010-01-28
    • US12558313
    • 2009-09-11
    • Thomas M. LoftusCraig A. TownsendGabriele RonnettM. Daniel LaneFrancis P. Kuhajda
    • Thomas M. LoftusCraig A. TownsendGabriele RonnettM. Daniel LaneFrancis P. Kuhajda
    • A61K31/365C12Q1/68A61K31/336
    • C12Q1/6883A61K31/365C12Q2600/106C12Q2600/136C12Q2600/158
    • This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly, or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA levels in the animal. Compounds administered according to this invention may be inhibitors of fatty acid synthase (FAS), including substituted α-methylene-β-carboxyl-γ-butyrolactones, or inhibitors of malonyl Coenzyme A decarboxylase (MCD). Preferably, the compound is administered in an amount sufficient to reduce the amount and/or duration of expression and/or secretion of NPY to levels at or below those observed for lean animals. In another preferred embodiment, the administration will reduce expression and/or secretion to levels observed for fed or satiated animals; more preferably, administration will reduce the level of NPY below that of fed animals. In a particular embodiment, this invention provides a method for inducing weight loss in an animal by administering a compound which inhibits feeding behavior in the animal. The method is particularly useful for inducing weight loss in animals deficient in expression of the hormone leptin or animals resistant to the action of leptin.
    • 本发明提供一种通过向动物施用降低神经肽Y(NPY)的表达和/或分泌的化合物来诱导动物体内的体重减轻的方法。 效果可以直接,间接或幽默地完成。 优选地,该化合物的给药具有增加动物中丙二酰辅酶A水平的作用。 根据本发明施用的化合物可以是脂肪酸合酶(FAS)的抑制剂,包括取代的α-亚甲基-β-羧基-γ-丁内酯或丙二酰辅酶A脱羧酶(MCD)的抑制剂。 优选地,化合物以足以将NPY的表达和/或分泌的量和/或持续时间降低至对于瘦动物观察到的水平或以下的量施用。 在另一个优选的实施方案中,施用将将表达和/或分泌降低至饲喂或饱食动物观察到的水平; 更优选地,施用将降低NPY的水平低于饲养动物的水平。 在一个具体实施方案中,本发明提供了通过施用抑制动物中的进食行为的化合物来诱导动物体重减轻的方法。 该方法特别可用于诱导缺乏激素瘦素或对瘦素作用的动物的表达的动物的体重减轻。
    • 6. 发明授权
    • Compounds, pharmaceutical compositions containing same, and methods of use for same
    • 含有其的化合物,药物组合物及其用途方法
    • US07649012B2
    • 2010-01-19
    • US10520505
    • 2003-07-09
    • Francis P. KuhajdaSusan M. MedghalchiJill M. McFaddenJagan Thupari
    • Francis P. KuhajdaSusan M. MedghalchiJill M. McFaddenJagan Thupari
    • A61K31/381C07D333/32
    • C07D409/12C07D333/32
    • A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IV wherein R21=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2OR25, —C(O)R25, —CO(O)R25, —C(O)NR25R26, —CH2C(O)R25, or —CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R22=—OH, —OR27, —OCH2C(O)R27, —OCH2C(O)NHR27, —OC(O)R27, —OC(O)OR27, —OC(O)NHNH—R5, or —OC(O)NR27R28, where R27 and R28 are each independently H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R27 and R28 can each optionally contain halogen atoms; R23 and R24, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.
    • 包含药物稀释剂和式IV化合物的药物组合物,其中R 21 = H,C 1 -C 20烷基,环烷基,烯基,芳基,芳基烷基或烷基芳基,-CH 2 OR 25,-C(O)R 25,-CO(O)R 25 ,-C(O)NR 25 R 26,-CH 2 C(O)R 25或-CH 2 C(O)NHR 25,其中R 25和R 26各自独立地为H,C 1 -C 10烷基,环烷基,烯基,芳基,芳烷基或烷芳基, 一个或多个卤素原子。 R22 = -OH,-OR27,-OCH2C(O)R27,-OCH2C(O)NHR27,-OC(O)R27,-OC(O)OR27,-OC(O)NHNH-R5或-OC )NR 27 R 28,其中R 27和R 28各自独立地为H,C 1 -C 20烷基,环烷基,烯基,芳基,芳基烷基或烷基芳基,并且其中R 27和R 28可各自任选含有卤素原子; R 23和R 24彼此相同或不同,为C 1 -C 20烷基,环烷基,烯基,芳基,芳基烷基或烷基芳基。 使用这些制剂治疗癌症,减轻体重,治疗基于微生物的感染,抑制神经肽Y和/或脂肪酸合成酶以及刺激CPT-1的方法。